Dec 13, 2022 / 10:30PM GMT
Christopher David O'Reilly - Takeda Pharmaceutical Company Limited - Global Head of IR & Global Finance
[Interpreted] Good morning. This is O'Reilly from the Global IR from the Takeda Pharmaceutical industry. So thank you very much for joining us for the webinar today for the TYK2 inhibitor NDI-034858.
And first, let me explain about the language setting. Select English.
Before starting, I'd like to remind everyone that we will be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factor that could cause our actual results to differ materially are discussed in our most recent Form 20-4 and in our other SEC filings. Please also refer to the important notice on Page 2.
So now I would like to move on to the presentation today. So first, I would like to invite our CEO, the Christophe Weber; and also the R&D President, Andy Plump, who is going to give the presentation and then followed by the question-and-answer session. So I
Takeda Pharmaceutical Co Ltd to Acquire Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics Call Transcript
Feb 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers